Valion Bio, Inc. Unrecognized Tax Benefits, Decrease Resulting from Current Period Tax Positions
Valion Bio, Inc. (VBIO) reported Unrecognized Tax Benefits, Decrease Resulting from Current Period Tax Positions of $17.00 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2025-03-21.
Financial Statements › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions · last filed 2025-03-21
- Valion Bio, Inc. unrecognized tax benefits, decrease resulting from current period tax positions for fiscal 2023 was $17.00K.
| Period end | Unrecognized Tax Benefits, Decrease Resulting from Current Period Tax Positions 12 month |
|---|---|
| 2023-12-31 | $17.00K 10-K · filed 2025-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |